reports
- Charlotte Vaisse
- Equipe Sustainability
- Luis de Toledo Heras
- Marc Lavaud
VLS VALNEVA SE
BAMNB KONINKLIJKE BAM GROEP NV
NEX NEXANS SA
ERA ERAMET SA
VID VIDRALA SA
KRN KRONES AG
CARM CARMILA SAS
IRES IRISH RESIDENTIAL PROPERTIES REIT PLC
SHOT SCANDIC HOTELS GROUP
SAFE SAFESTORE HOLDINGS PLC
VGP VGP NV
BRAV BRAVIDA HOLDING AB
FTG111 FLATEXDEGIRO AG
TKO TIKEHAU CAPITAL SCA
DUE DURR AG
2CRSI 2CRSI SA
AZE AZELIS GROUP NV
AF AIR FRANCE - KLM
LOCAL SOLOCAL GROUP
- Charlotte Vaisse
- Equipe Sustainability
- Luis de Toledo Heras
- Marc Lavaud
VLS VALNEVA SE
BAMNB KONINKLIJKE BAM GROEP NV
NEX NEXANS SA
ERA ERAMET SA
VID VIDRALA SA
KRN KRONES AG
CARM CARMILA SAS
IRES IRISH RESIDENTIAL PROPERTIES REIT PLC
SHOT SCANDIC HOTELS GROUP
SAFE SAFESTORE HOLDINGS PLC
VGP VGP NV
BRAV BRAVIDA HOLDING AB
FTG111 FLATEXDEGIRO AG
TKO TIKEHAU CAPITAL SCA
DUE DURR AG
2CRSI 2CRSI SA
AZE AZELIS GROUP NV
AF AIR FRANCE - KLM
LOCAL SOLOCAL GROUP
- Martial Descoutures
- Martial Descoutures
Valneva meldet vorläufige ungeprüfte Umsätze und liquide Mittel für 20...
Valneva meldet vorläufige ungeprüfte Umsätze und liquide Mittel für 2025; gibt einen Ausblick für 2026 Gesamtumsatz von 174,7 Millionen Euro im Rahmen der Prognose, davon 157,9 Millionen Euro aus Produktumsatz Starke Liquiditätsposition zum Jahresende in Höhe von 109,7 Millionen Euro, mit verbesserter finanzieller Flexibilität nach erfolgreicher Umschuldung 2026 könnte ein Jahr des Wandels werden, da in der ersten Jahreshälfte Daten zur Phase 3 der Lyme-Borreliose-Studie erwartet werden Der Vertrag des Chief Executive Officers wurde um weitere drei Jahre verlängert, wodurch die Kontinuität...
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provid...
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the yearChief Executive Officer’s contract renewed for a further three-year term, ensuring continuity in leadership Lyon (France), February 19, 2026 – (Nasdaq: VALN; Euronext Paris...
Valneva publie son chiffre d’affaires et sa trésorerie non audités pou...
Valneva publie son chiffre d’affaires et sa trésorerie non audités pour l’exercice 2025 et fournit ses prévisions pour l’exercice 2026 Chiffre d’affaires de 174,7millions d’euros en ligne avec les prévisions, dont 157,9 millions d’euros de ventes de vaccinsSolide position de trésorerie de 109,7 millions d’euros à fin 2025 et flexibilité financière renforcée suite au refinancement réussi de la dette 2026 pourrait être une année transformatrice pour Valneva, avec des données de Phase 3 sur le vaccin Lyme attendues au premier semestre.Mandat du Directeur Général de Valneva renouvelé pour une...
Elis: Amy Flikerski steps down from the Elis Supervisory Board
Elis: Amy Flikerski steps down from the Elis Supervisory Board Amy Flikerski steps down from the Elis Supervisory Board Puteaux, 19 February 2026 – Amy Flikerski, a member of the Supervisory Board of Elis since June 2020, originally proposed by CPP Investments, has informed Elis that she was resigning from her duties of the Supervisory Board of Elis, effective February 18, 2026. In this role, she also served on the Corporate Social Responsibility Committee. This decision follows the sale of 7,027,199 Elis shares announced on February 12, 2026, and is in accordance with the governance agre...
Elis : Amy Flikerski quitte le Conseil de surveillance d'Elis
Elis : Amy Flikerski quitte le Conseil de surveillance d'Elis Amy Flikerski quitte le Conseil de surveillance d'Elis Puteaux, le 19 février 2026 – Amy Flikerski, membre du Conseil de surveillance d’Elis depuis juin 2020, nommée sur proposition de CPP Investments, a informé Elis qu’elle démissionnait du Conseil de surveillance avec effet au 18 février 2026. Amy Flikerski était également membre du comité responsabilité sociale, environnementale et sociétale. Cette décision fait suite à la cession de 7 027 199 actions Elis, annoncée le 12 février 2026, et s’inscrit dans le cadre de l’accord ...
X-Fab Silicon Foundries SE: 1 director
A director at X-Fab Silicon Foundries SE bought 5,500 shares at 4.390EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Elis: Disclosure of trading in own shares occured from February 9 to F...
Elis: Disclosure of trading in own shares occured from February 9 to February 13, 2026 Disclosure of trading in own shares occurred from February 9 to February 13, 2026 Puteaux, February 17, 2026 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from February 9 to February 13, 2026 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025: Aggregated presentation: Issuer nameIssuer code(LEI) Transaction dateISIN CodeDaily total Volu...
Elis : Déclaration des transactions sur actions propres du 9 février a...
Elis : Déclaration des transactions sur actions propres du 9 février au 13 février 2026 Déclaration des transactions sur actions propres réalisées du 9 février au 13 février 2026 Puteaux, le 17 février 2026 Conformément à la réglementation relative aux rachats d’actions, notamment le Règlement (UE) 2016/1052, Elis déclare ci-après les achats d’actions propres réalisés du 9 février 2026 au 13 février 2026 dans le cadre du programme de rachat autorisé par la 24ème résolution de l’assemblée générale des actionnaires du 22 mai 2025 : Présentation agrégée : Nom del'émetteurCode Identi...
- Ahmed Ben Salem
- Baptiste Lebacq
- Bruno Cavalier
OUT1V OUTOKUMPU OYJ
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
PBB DEUTSCHE PFANDBRIEFBANK AG
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
01913 PRADA S.P.A.
ADVI ADVINI
GNFT GENFIT SA
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
TINC TINC COMM. VA
MAU ETABLISSEMENTS MAUREL & PROM SA
ZGN ERMENEGILDO ZEGNA NV
FI-N GEORG FISCHER AG
DEME DEME GROUP NV
- Ahmed Ben Salem
- Baptiste Lebacq
- Bruno Cavalier
OUT1V OUTOKUMPU OYJ
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
PBB DEUTSCHE PFANDBRIEFBANK AG
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
01913 PRADA S.P.A.
ADVI ADVINI
GNFT GENFIT SA
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
TINC TINC COMM. VA
MAU ETABLISSEMENTS MAUREL & PROM SA
ZGN ERMENEGILDO ZEGNA NV
FI-N GEORG FISCHER AG
DEME DEME GROUP NV
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
Valneva fait un point sur l’utilisation du vaccin IXCHIQ® au Royaume-...
Valneva fait un point sur l’utilisation du vaccin IXCHIQ® au Royaume-Uni Lyon (France), le 13 février 2026 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui qu’à la suite d’une revue des bénéfices et risques du vaccin contre le chikungunya de la société, IXCHIQ®, la Commission britannique des médicaments à usage humain (CHM) a mis à jour ses recommandations concernant l’utilisation de ce vaccin. Les informations de prescription (PI) mises à jour refléteront ces recommandations, qui incluent désormais une restriction pour les personnes de...
Valneva Provides Update on Recommendations for Use of IXCHIQ® in the U...
Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom Lyon (France), February 13, 2026 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company’s single‑dose chikungunya vaccine, IXCHIQ®, the United Kingdom’s (UK) Commission on Human Medicines (CHM) has updated its recommendations for use of the vaccine. The updated Prescribing Information (PI) will reflect these recommendations, which now include a restriction for individuals over 60 years of age, for people with sp...
Elis: 1 director
A director at Elis bought 7,027,199 shares at 25.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the U...
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule1Ipsen confirmed its commitment to launch a Phase 3 in PSC, creating a new avenue for potential future upside for GENFITGENFIT’s CCA Phase 1b study progressing as planned: New dose-escalation cohort fully enrolled with no dose-limiting toxicities reported at the 21-day timepoint Phase 1b data readout ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.